Effect of amifostine on survival among patients treated with radiotherapy: A meta-analysis of individual patient data

Journal of Clinical Oncology

Volumn 29, Issue 18, 2011, Pages 2590-2597

  Bourhis, Jean ^a   Blanchard, Pierre ^a   Maillard, Emilie ^a   Brizel, David M ^b   Movsas, Benjamin ^c   Buentzel, Jens ^d   Langendijk, Johannes A ^e   Komaki, Ritsuko ^g   Leong, Swan Swan ^h   Levendag, Peter ^f   Pignon, Jean Pierre ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c HENRY FORD HOSPITAL   (United States)

^d Suedharzkrankenhaus Nodhausen   (Germany)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f ERASMUS MEDICAL CENTER   (Netherlands)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE;

AGE; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; DRUG EFFECT; DRUG EFFICACY; FOLLOW UP; GENETIC HETEROGENEITY; HAZARD RATIO; HEAD AND NECK CARCINOMA; HISTOLOGY; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; META ANALYSIS; OVERALL SURVIVAL; PELVIS CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SEX; SQUAMOUS CELL CARCINOMA; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AMIFOSTINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASMS; RADIATION INJURIES; RADIATION-PROTECTIVE AGENTS; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT FAILURE; UTERINE CERVICAL NEOPLASMS;

EID: 79959311310     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.33.1454     Document Type: Article

References (57)

1. Aupérin A, Le Pechoux C, Rolland E, et al: Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non - smallcell lung cancer. J Clin Oncol 28:2181-2190, 2010
2. Bourhis J, Overgaard J, Audry H, et al: Hyperfractionated or accelerated radiotherapy in head and neck cancer: A meta-analysis. Lancet 368:843-854, 2006 (Pubitemid 44292807)
3. Pignon JP, le Maitre A, Maillard E, et al: Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiother Oncol 92:4-14, 2009
4. Bohlius J, Schmidlin K, Brillant C, et al: Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: A meta-analysis of randomised trials. Lancet 373:1532-1542, 2009
5. Brizel DM, Wasserman TH, Henke M, et al: Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 18:3339-3345, 2000
6. Movsas B, Scott C, Langer C, et al: Randomized trial of amifostine in locally advanced non-smallcell lung cancer patients receiving chemotherapy and hyperfractionated radiation: Radiation therapy oncology group trial 98-01. J Clin Oncol 23:2145-2154, 2005 (Pubitemid 46218706)
7. Mell LK, Malik R, Komaki R, et al: Effect of amifostine on response rates in locally advanced non-small-cell lung cancer patients treated on randomized controlled trials: A meta-analysis. Int J Radiat Oncol Biol Phys 68:111-118, 2007 (Pubitemid 46589830)
8. Sasse AD, Clark LG, Sasse EC, et al: Amifostine reduces side effects and improves complete response rate during radiotherapy: Results of a meta-analysis. Int J Radiat Oncol Biol Phys 64:784-791, 2006 (Pubitemid 43183575)
9. Pignon JP, Hill C: Meta-analyses of randomised clinical trials in oncology. Lancet Oncol 2:475-482, 2001
10. Piedbois P, Buyse M: Meta-analyses based on abstracted data: A step in the right direction, but only a first step. J Clin Oncol 22:3839-3841, 2004 (Pubitemid 41079861)
11. Stewart LA, Parmar MK: Meta-analysis of the literature or of individual patient data: Is there a difference? Lancet 341:418-422, 1993
12. Stewart LA, Clarke MJ: Practical methodology of meta-analyses (overviews) using updated individual patient data: Cochrane Working Group. Stat Med 14:2057-2079, 1995
13. Yusuf S, Peto R, Lewis J, et al: Beta blockade during and after myocardial infarction: An overview of the randomized trials. Prog Cardiovasc Dis 27:335-371, 1985 (Pubitemid 15107153)
14. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials - Non-small Cell Lung Cancer Collaborative Group. BMJ 311:899-909, 1995
15. Higgins JP, Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539-1558, 2002 (Pubitemid 34746062)
16. Schemper M, Smith TL: A note on quantifying follow-up in studies of failure time. Control Clin Trials 17:343-346, 1996 (Pubitemid 26342716)
17. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women - Early Breast Cancer Trialists' Collaborative Group. Lancet 339:71-85, 1992
18. Kligerman MM, Liu T, Liu Y, et al: Interim analysis of a randomized trial of radiation therapy of rectal cancer with/without WR-2721. Int J Radiat Oncol Biol Phys 22:799-802, 1992
19. Niibe H, Takahashi I, Mitsuhashi N, et al: [An evaluation of the clinical usefulness of amifostine (YM-08310), radioprotective agent: A double-blind placebo-controlled study. 1. Head and neck tumors]. Nippon Gan Chiryo Gakkai Shi 20:984-993, 1985 (Pubitemid 15037396)
20. Niibe H, Takahashi I, Miyaishi K, et al: [An evaluation of the clinical usefulness of amifostine (YM-08310), radioprotective agent: A double-blind placebo-controlled study. 2. Abdominal and pelvic tumors]. Nippon Gan Chiryo Gakkai Shi 20:994-1001, 1985 (Pubitemid 15037397)
21. Takahashi M, Abe M, Kawamura T, et al: [Radioprotective effect of YM-08310 in radiotherapy of cervical cancer]. Nippon Igaku Hoshasen Gakkai Zasshi 42:435-442, 1982
22. Peters K, Mucke R, Hamann D, et al: Supportive use of amifostine in patients with head and neck tumors undergoing radio-chemotherapy: Is it possible to limit the duration of the application of amifostine? Strahlenther Onkol 175:23-26, 1999 (suppl 4)
23. Kouloulias VE, Kouvaris JR, Pissakas G, et al: A phase II randomized study of topical intrarectal administration of amifostine for the prevention of acute radiation-induced rectal toxicity. Strahlenther Onkol 180:557-562, 2004 (Pubitemid 39248788)
24. Leung SF, Teo P, Zee B, et al: Subcutaneous amifostine for reduction of radiation xerostomia in nasopharynx cancer: A prospective randomised study. J Clin Oncol 23:463s, 2005 (suppl; abstr 8043)
25. Antonadou D, Athanassiou H, Sarris G, et al: Randomized phase III trial of chemoradiation treatment +/-amifostine in patients with colorectal cancer. Proc Am Soc Clin Oncol 22:S325, 2003 (abstr 1176)
26. Antonadou D, Coliarakis N, Synodinou M, et al: Randomized phase III trial of radiation treatment +/- amifostine in patients with advanced-stage lung cancer. Int J Radiat Oncol Biol Phys 51:915-922, 2001 (Pubitemid 33028882)
27. Antonadou D, Pepelassi M, Synodinou M, et al: Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. Int J Radiat Oncol Biol Phys 52:739-747, 2002 (Pubitemid 34158737)
28. Antonadou D, Throuvalas N, Petridis A, et al: Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 57:402-408, 2003 (Pubitemid 37040936)
29. Athanassiou H, Antonadou D, Coliarakis N, et al: Protective effect of amifostine during fractionated radiotherapy in patients with pelvic carcinomas: Results of a randomized trial. Int J Radiat Oncol Biol Phys 56:1154-1160, 2003 (Pubitemid 36794050)
30. Bourhis J, De Crevoisier R, Abdulkarim B, et al: A randomized study of very accelerated radiotherapy with and without amifostine in head and neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 46:1105-1108, 2000 (Pubitemid 30139418)
31. Braaksma M, van Agthoven M, Nijdam W, et al: Costs of treatment intensification for head and neck cancer: Concomitant chemoradiation randomised for radioprotection with amifostine. Eur J Cancer 41:2102-2111, 2005 (Pubitemid 41337952)
32. Buentzel J, Micke O, Adamietz IA, et al: Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: A randomized placebocontrolled phase III study. Int J Radiat Oncol Biol Phys 64:684-691, 2006 (Pubitemid 43183561)
33. Büntzel J, Glatzel M, Kuttner K, et al: Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer. Semin Radiat Oncol 12:4-13, 2002 (Pubitemid 34246062)
34. Gallardo D, Mohar A, Calderillo G, et al: Cisplatin, radiation, and amifostine in carcinoma of the uterine cervix. Int J Gynecol Cancer 9:225-230, 1999 (Pubitemid 29302858)
35. Giglio R, Mickiewicz E, Pradier E, et al: Alternating chemotherapy (CT) + radiotherapy (RT) with amifostine (A) protection for head and neck cancer (HN). Early stop of a randomized trial. Proc Am Soc Clin Oncol 15:106, 1997 (abstr 1639)
36. Jellema AP, Slotman BJ, Muller MJ, et al: Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: A prospective randomized study in squamous cell head and neck cancer. Cancer 107:544-553, 2006 (Pubitemid 44107215)
37. Komaki R, Lee JS, Kaplan B, et al: Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: Preliminary results. Semin Radiat Oncol 12:46-49, 2002 (Pubitemid 34246068)
38. Koukourakis MI, Kyrias G, Kakolyris S, et al: Subcutaneous administration of amifostine during fractionated radiotherapy: A randomized phase II study. J Clin Oncol 18:2226-2233, 2000 (Pubitemid 30350214)
39. Kouvaris J, Kouloulias V, Malas E, et al: Amifostine as radioprotective agent for the rectal mucosa during irradiation of pelvic tumors: A phase II randomized study using various toxicity scales and rectosigmoidoscopy. Strahlenther Onkol 179:167-174, 2003 (Pubitemid 36313771)
40. Leong SS, Tan EH, Fong KW, et al: Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer. J Clin Oncol 21:1767-1774, 2003 (Pubitemid 46638590)
41. Patni N, Patni S, Bapna A, et al: The role of amifostine in prophylaxis of radiotherapy induced mucositis and xerostomia in head and neck cancer. J Clin Oncol 22:505s, 2004 (suppl; abstr 5568)
42. Senzer N: A phase III randomized evaluation of amifostine in stage IIIA/IIIB non-small cell lung cancer patients receiving concurrent carboplatin, paclitaxel, and radiation therapy followed by gemcitabine and cisplatin intensification: Preliminary findings. Semin Oncol 29:38-41, 2002
43. Vacha P, Fehlauer F, Mahlmann B, et al: Randomized phase III trial of postoperative radiochemotherapy +/- amifostine in head and neck cancer: Is there evidence for radioprotection? Strahlenther Onkol 179:385-389, 2003
44. Veerasarn V, Phromratanapongse P, Suntornpong N, et al: Effect of Amifostine to prevent radiotherapy-induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. J Med Assoc Thai 89:2056-2067, 2006 (Pubitemid 44956685)
45. Michiels S, Piedbois P, Burdett S, et al: Metaanalysis when only the median survival times are known: A comparison with individual patient data results. Int J Technol Assess Health Care 21:119-125, 2005 (Pubitemid 40229377)
46. Sarna L, Swann S, Langer C, et al: Clinically meaningful differences in patient-reported outcomes with amifostine in combination with chemoradiation for locally advanced non-small-cell lung cancer: An analysis of RTOG 9801. Int J Radiat Oncol Biol Phys 72:1378-1384, 2008
47. Monroe AT, Reddy SC, Gibbs GL, et al: Factors associated with radiation-induced nausea and vomiting in head and neck cancer patients treated with intensity modulated radiation therapy. Radiother Oncol 87:188-194, 2008
48. Valeyrie-Allanore L, Poulalhon N, Fagot JP, et al: Stevens-Johnson syndrome and toxic epidermal necrolysis induced by amifostine during head and neck radiotherapy. Radiother Oncol 87:300-303, 2008
49. Rades D, Fehlauer F, Bajrovic A, et al: Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients. Radiother Oncol 70:261-264, 2004 (Pubitemid 38520157)
50. van der Laan HP, van den Bergh A, Schilstra C, et al: Grading-system-dependent volume effects for late radiation-induced rectal toxicity after curative radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 70:1138-1145, 2008 (Pubitemid 351296104)
51. Wasserman TH, Brizel DM, Henke M, et al: Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and- neck cancer: 2-year follow-up of a prospective, randomized, phase III trial. Int J Radiat Oncol Biol Phys 63:985-990, 2005 (Pubitemid 41505273)
52. van de Water TA, Bijl HP, Westerlaan HE, et al: Delineation guidelines for organs at risk involved in radiation-induced salivary dysfunction and xerostomia. Radiother Oncol 93:545-552, 2009
53. Rudat V, Munter M, Rades D, et al: The effect of amifostine or IMRT to preserve the parotid function after radiotherapy of the head and neck region measured by quantitative salivary gland scintigraphy. Radiother Oncol 89:71-80, 2008
54. Nutting CM, Morden JP, Harrington KJ, et al: Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): A phase 3 multicentre randomised controlled trial. Lancet Oncol 12:127-136, 2011
55. Thorstad WL, Chao KS, Haughey B: Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer. Semin Oncol 31:8-12, 2004 (Pubitemid 40250137)
56. Rosenthal DI, Chambers MS, Weber RS, et al: A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing. Semin Oncol 31:25-28, 2004 (Pubitemid 40250140)
57. Mangoni M, Yue X, Morin C, et al: Differential effect triggered by a heparan mimetic of the RGTA family preventing oral mucositis without tumor protection. Int J Radiat Oncol Biol Phys 74:1242-1250, 2009